Raltegravir is an HIV integrase inhibitor. Currently it is the only approved integrase inhibitor. Some women with HIV who take antiretroviral medications find that they notice changes in their body or weight gain. This study will look at whether using raltegravir can lessen weight gain or body changes in women with HIV using antiretroviral medications.

Inclusion criteria:

• Documented HIV infection
• Female 18 years or older
• Documented central fat accumulation
• Documented viral load of less than 50 copies/mL at screening and less than 400 copies/mL in the past 6 months
• Current antiretroviral therapy with two nucleoside analogues and either a non-nucleoside analogue (nevirapin, efavirenz or TMC125) or an approved protease inhibitor
• Women who can get pregnant will need a negative pregnancy test within 48 hours prior to entry
• Ability and willingness to provide informed consent

Exclusion criteria:

• no history of virologic failure or resistance to current ART regimen
• Pregnancy: current or within the past six months or breast feeding
• Prior treatment history that would not allow the use of Truvada or epzicom
• No change in metformin or thiazolidinediones for 12 weeks prior to entry
• Use of growth hormone releasing factor in the last 6 months
• Change or initiation of anti-hyperlipemic regimen within 3 months prior to study
• Current use of androgen therapy
• Intent to modify diet, exercise habits or to enroll in a weight-loss intervention during the study period
• Current or projected need to use rifampin, dilantin or phenobarbital during the 48 week study period.

This study is being conducted by Dr. Judith Currier under IRB #07-09-055-01

If you think you might be interested in participating in this study, please contact Blanca Corea at 310-557-9062 or email at bcorea@mednet.ucla.edu

Return to Clinical Trials main page